We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Executive Changes at Stem Cell Therapeutics Corp
News

Executive Changes at Stem Cell Therapeutics Corp

Executive Changes at Stem Cell Therapeutics Corp
News

Executive Changes at Stem Cell Therapeutics Corp

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Executive Changes at Stem Cell Therapeutics Corp"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Allen Davidoff has accepted an offer from the Board of Directors and will become the Company's Chief Scientific Officer. The Board of Directors will immediately begin a search for a new President and temporarily assume a more active role in managing the company including the possibility of naming an interim CEO.

Dean Peterson, Chairman of SCT stated, "We wish to thank Alan Moore for his past contributions and wish him all the best in his future endeavors. We will take our time in selecting the right leader for the company. We are committed and determined to build a solid base for SCT and have some great opportunities ahead of us."

About Stem Cell Therapeutics Corp: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair neurological function lost due to disease or injury. SCT's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Advertisement